Scilex Holding Company Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was -153.85K shares, a 641125.00% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 53.00K shares, a 24782.63% increase year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 100.95K shares, a 78770.31% increase year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 46.00 shares.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 154.00 shares, a 57.81% decline from fiscal 2023.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 365.00 shares, a 99.82% decline from fiscal 2022.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 202.00K shares.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares, a 100.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | -153.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 154.00 shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 53.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | 154.02K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | 100.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 101.24K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | 46.00 shares 10-Q · filed 2025-05-14 | 411.00 shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 24.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 365.00 shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 213.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | |
| 2023-06-30 | 128.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-12 | |
| 2022-12-31 | 202.00K shares 10-K · filed 2023-03-07 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-07 | |
| 2020-12-31 | 38.00K shares 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |